If you've been searching for Zepbound in India, you've probably found that pharmacies don't carry it and the online sellers offering it are unverified. This page explains, factually, why — and what the situation actually is.
This information has been reviewed by Dr. Manuj Sondhi (MRCP UK), Consultant Physician and Diabetologist at Nirvana Clinic, Greater Noida. It is general information, not medical advice, and not an offer to sell or supply any medicine.
Zepbound and Mounjaro — the Same Molecule
The most useful fact for anyone researching this topic:
Weekly injection
Weekly injection
Both Zepbound and Mounjaro contain the same active molecule, tirzepatide, from the same manufacturer. The differences are the brand name and the approved indication — abroad, Zepbound is approved for chronic weight management, while in India the same molecule is marketed as Mounjaro and is approved for type-2 diabetes. From a pharmacological standpoint the molecule is the same; what differs is the label and the regulatory approval in each country.
Why Zepbound Hasn't Launched in India
The manufacturer received approval from India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), for Mounjaro (tirzepatide) for type-2 diabetes, and Mounjaro is available in India. The separate, obesity-specific indication — which is what is marketed abroad as Zepbound — is understood to be under regulatory review and has not been approved in India.
No confirmed launch date for an obesity-indicated tirzepatide product in India has been announced. As a general point of medical practice, decisions about whether any medicine is appropriate for a particular patient — including any use outside an approved indication — rest with a registered physician on a case-by-case basis after individual assessment. This is not something a patient should arrange independently.
A Note on Cost
People often ask how much tirzepatide costs. Prices vary by brand, dose, formulation, city and pharmacy, and change over time. Because cost should never be the basis for a medical decision, this page does not provide drug prices. For accurate, current pricing, ask a registered physician or a licensed pharmacy.
⛔ Please Avoid the Grey Market
Some sellers and social-media accounts claim to sell imported Zepbound. This is strongly inadvisable. These are prescription medicines, and obtaining them outside the regulated system is unsafe.
- Cold-chain failure. Tirzepatide must be kept refrigerated (2–8°C). Pens shipped through unrefrigerated couriers or held in transit can lose potency or become unsafe.
- Counterfeit risk. Global health agencies have flagged counterfeit GLP-1 pens in grey markets. You cannot verify what an unbranded or smuggled vial actually contains.
- No medical supervision. Tirzepatide has serious contraindications (medullary thyroid carcinoma, MEN-2, pancreatitis history) and side effects that require monitoring. Self-injecting without a physician is dangerous.
- Customs seizure. Personal importation of unapproved drugs into India is restricted under the Drugs and Cosmetics Act, and packages may be seized.
If weight or metabolic health is a concern, the safe path is always to consult a qualified physician — never an online seller.
How Tirzepatide Treatment Is Approached Clinically
For general understanding only: where a physician determines that a GLP-1 or GIP/GLP-1 medicine is appropriate for a patient, supervised treatment typically involves an eligibility assessment (including screening for contraindications), baseline investigations, gradual dose titration to limit side effects, and ongoing monitoring with follow-up. This is medical care delivered on an individual basis — not a product that should be purchased and self-administered.
If you have a question about your own weight or metabolic health, the right step is a consultation with a registered physician who can assess your individual situation. General clinic contact details are at the foot of this page.
Tirzepatide and Semaglutide — What's Available in India
For context, here is the availability status of the main medicines in this category in India (this is factual status only, not a comparison or recommendation of any product):
| Medicine | Molecule | Form | India Status |
|---|---|---|---|
| Mounjaro | Tirzepatide | Weekly injection | Approved (type-2 diabetes) |
| Zepbound | Tirzepatide | Weekly injection | Not approved/launched |
| Ozempic | Semaglutide | Weekly injection | Approved (type-2 diabetes) |
| Wegovy | Semaglutide | Weekly injection | Available |
| Generic semaglutide | Semaglutide | Vial / pen | Available since 2026 |
| Rybelsus | Semaglutide (oral) | Daily tablet | Available |
Further educational reading: Generic Semaglutide in India 2026 · Ozempic in India 2026 · Semaglutide vs Tirzepatide